PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
-9.04%
Negative operating income growth while CRVO is at 79.45%. Joel Greenblatt would press for urgent turnaround measures.
48.96%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
53.59%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
51.99%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
10.21%
Share count expansion well above CRVO's 5.35%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.42%
Diluted share count expanding well above CRVO's 5.35%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Negative OCF growth while CRVO is at 38.88%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.23%
Negative FCF growth while CRVO is at 38.88%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-15675.30%
Negative 5Y OCF/share CAGR while CRVO is at 2.63%. Joel Greenblatt would question the firm’s operational model or cost structure.
-5709.37%
Negative 3Y OCF/share CAGR while CRVO stands at 93.28%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-6744.35%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20067.21%
Negative 5Y net income/share CAGR while CRVO is 27.32%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-6838.40%
Negative 3Y CAGR while CRVO is 87.54%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
530.49%
5Y equity/share CAGR above 1.5x CRVO's 14.17%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
431.75%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Negative asset growth while CRVO invests at 1537.87%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-71.36%
We have a declining book value while CRVO shows 29.82%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while CRVO stands at 24.10%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
52.82%
R&D growth of 52.82% while CRVO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-14.04%
We cut SG&A while CRVO invests at 27.42%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.